Omega Ther­a­peu­tic­s' epige­nom­ic med­i­cines re­duce MYC ex­pres­sion by 55% in ear­ly study of can­cer pa­tients

Omega Ther­a­peu­tics, a com­pa­ny de­sign­ing ge­net­ic med­i­cines that di­al the out­put of genes up or down, on Tues­day morn­ing re­vealed the first da­ta from a clin­i­cal tri­al of its so-called epige­nom­ic con­trollers.

The treat­ment re­press­es the no­to­ri­ous MYC gene, which is linked to many can­cers but has proven dif­fi­cult to tar­get. The com­pa­ny test­ed two dos­es of its ther­a­py in eight peo­ple with he­pa­to­cel­lu­lar car­ci­no­ma — the most com­mon form of liv­er can­cer — or oth­er sol­id tu­mors where MYC is of­ten a cul­prit.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER